GHIC Makes Initial Global Health Security Portfolio Investment Following the Launch of its BARDA Partnership

SAN DIEGO, CA — Biolinq Incorporated, a medical device company developing a wearable biosensor platform that measures biomarkers important to the management of many clinical conditions, has announced the closing of a $100 million Series B financing round led by RiverVest Venture Partners.  Global Health Investment Corporation participated in the round with its initial global health security portfolio investment under its BARDA partnership. With the closing of the transaction, Zina Affas Besse, a Senior Advisor to GHIC, has joined the company’s board of directors.  

Biolinq has developed a micro-array of biosensors to measure interstitial fluid glucose levels just under the surface of the skin, leveraging innovation from the semiconductor industry to miniaturize electrochemical sensors designed for precision manufacturing and significant scale. Biolinq’s initial leading indication is monitoring glucose, although the company is developing a platform that can multiplex different analytes with the potential to predict or detect exposure to multiple public health agents.

Learn more in Biolinq’s press release or at www.Biolinq.com